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ARTICLE
Noninvasive liquid diet delivery of stable isotopes
into mouse models for deep metabolic network
tracing
Ramon C. Sun1, Teresa W.-M. Fan 1,2, Pan Deng1, Richard M. Higashi1,2, Andrew N. Lane1,2,
Anh-Thu Le3, Timothy L. Scott1, Qiushi Sun 1, Marc O. Warmoes1 & Ye Yang1,2
Delivering isotopic tracers for metabolic studies in rodents without overt stress is challenging.
Current methods achieve low label enrichment in proteins and lipids. Here, we report non-
invasive introduction of 13C6-glucose via a stress-free, ad libitum liquid diet. Using NMR and
ion chromatography-mass spectrometry, we quantify extensive 13C enrichment in products of
glycolysis, the Krebs cycle, the pentose phosphate pathway, nucleobases, UDP-sugars, gly-
cogen, lipids, and proteins in mouse tissues during 12 to 48 h of 13C6-glucose feeding.
Applying this approach to patient-derived lung tumor xenografts (PDTX), we show that the
liver supplies glucose-derived Gln via the blood to the PDTX to fuel Glu and glutathione
synthesis while gluconeogenesis occurs in the PDTX. Comparison of PDTX with ex vivo
tumor cultures and arsenic-transformed lung cells versus xenografts reveals differential
glucose metabolism that could reflect distinct tumor microenvironment. We further found
differences in glucose metabolism between the primary PDTX and distant lymph node
metastases.
DOI: 10.1038/s41467-017-01518-z OPEN
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Stable isotope tracer approaches, here termed Stable IsotopeResolved Metabolomics (SIRM) are becoming widely usedfor studying cancer metabolism1, 2. These approaches not
only improved understanding of known metabolic phenotypes in
cancer cells such as enhanced glycolysis (the Warburg effect3) and
glutaminolysis1, 4, but also revealed novel metabolic reprogram-
ming crucial to tumor growth or survival to enable discovery of
new therapeutic targets2, 5, 6. Most tracer studies have been per-
formed in vitro using cell lines, which lack the tumor micro-
environment and 3D architecture that may be crucial to
recapitulate the transcriptional and metabolic programs in vivo.
However, in vivo tracer studies remain challenging, due in part to
the overt stress induced by animal handling with existing tech-
niques, which also limits the duration of tracer delivery.
There are several established means of administering 13C-
glucose tracers in vivo, including bolus injections via the tail vein7
and continuous infusion via cannulation8, 9. These methods may
suffer from the well-documented effects on metabolism due to
anesthesia10, 11 and/or physical trauma12, 13, thereby confounding
the metabolic signatures of tumors. Although these invasive
methods can achieve high 13C-glucose levels in mouse plasma,
tracer experiments are transient in nature (e.g., 30–150 min) to
reduce stress responses induced by anesthesia or physical con-
straint. As such, 13C labeling is often limited to metabolites of the
faster turnover pathways such as glycolysis and the Krebs cycle7, 8
but not the metabolome of more extended pathways such as de
novo synthesis of lipids, proteins, and nucleotides. A better
method of introducing stable isotope tracers is needed that avoids
overt stress, while enabling long-term tracer administration for
deeper pathway coverage in vivo.
Here, we report a non-invasive method of administering 13C6-
glucose to mouse models via liquid diet feeding to achieve deep
metabolic network coverage. We have applied this method to
non-small cell lung cancer patient-derived tumor xenografts and
arsenite-transformed lung cell xenografts to assess the influence
of the microenvironment on cancer cell metabolism.
Results
A liquid diet for in vivo 13C enrichment of metabolites. Here
we describe a new method to introduce 13C-glucose via an ad
libitum liquid diet that is stress-free, highly reproducible, and
achieves relatively high enrichment of complex carbohydrates,
nucleotides, lipids and proteins in major organs of NOD/SCID/
Gamma (NSG) mice in <24 h. We designed a liquid diet formula
in which glucose is the primary source of carbohydrate (Fig. 1a).
Mice were habituated to an unlabeled glucose liquid diet for
2 days to achieve stable daily food intake (Fig. 1b). On day 3, the
dietary carbohydrate was replaced with 13C6-glucose. On
the basis of the daily mouse-feeding pattern (Fig. 1c), we supplied
the enriched liquid diet at 1600 hours, followed by necropsy at
1000 hours on the next day. Mouse organs were dissected, flash
frozen in liquid nitrogen (LiqN2), and extracted for polar meta-
bolites, lipids and proteins, then analyzed by NMR and mass
spectrometry.
Isotopic steady state is achieved in livers of 13C-fed mice. To
investigate the approach to isotopic steady state in NSG mice fed
with the 13C6-glucose liquid diet, we performed a time course
study by habituating 15 mice to an unlabeled glucose liquid diet
for 48 h to achieve stable daily food intake, followed by fasting for
6 h then switching to the 13C6-glucose diet (Fig. 1b). At 0, 12, 36,
and 48 h after the switch, the mice were killed, followed by organ
dissection and flash freezing of organs in LiqN2. Metabolites
extracted from the liver of each mouse were analyzed by ion
chromatography coupled to ultra high-resolution Fourier trans-
form MS (IC-UHR-FTMS) to profile metabolites and their 13C
labeling patterns (Fig. 2).
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Fig. 1 Procedure for tracing glucose metabolism in vivo. a Composition of liquid diet used for 13C6-glucose tracer feeding (presented as g/kg and %kcal for
each ingredient). The constituted liquid diet provides ca. 1000 kcal/l and a 20 g mouse is expected to consume 12.6 kcal a day. b Experimental workflow for
tracking glucose metabolism in vivo. Mice were fed ad libitum 13C6-glucose enriched diet for 18 h, after which blood was collected, and organs were
dissected, snap frozen and pulverized in liquid nitrogen. Samples were then extracted into three fractions: polar, protein, and lipids. Each fraction was
analyzed by NMR and/or Mass Spectrometry as described in the Methods. c Feeding pattern of an NSG mouse over 18 h
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The fractional enrichment in the 13C1 to 13C3-isotopologues of
glycolytic metabolites 1,3-bisphosphoglycerate (1,3-BPG, Fig. 2a),
3-phosphoglycerate (3PG, Fig. 2b) and lactate (Fig. 2c), was
essentially constant from 12 to 48 h in the liver, indicating that
isotopic steady-state was reached by 12 h for glycolysis. This was
also the case for the Krebs cycle in the liver, as indicated by the
constancy of the fractional enrichment in all of the 13C-
isotopologues of the Krebs cycle metabolites citrate (Fig. 2d),
succinate (Fig. 2e) and malate (Fig. 2f) after 12 h. To determine
whether isotopic steady state was reached for metabolites further
down the pathways, we measured the fractional 13C enrichment
of nucleotides and nucleotide sugars. All of the significant 13C
isotopologues of UTP (13C1-7, Fig. 2g) and uridine diphosphate
N-acetylglucosamine (UDPGlcNAc, 13C7, 13C9-15-isotopologues,
Fig. 2j) reached isotopic steady state by 12 h except for the 13C6-
and 13C 8-isotopologues of UDPGlcNAc. UDP-GlcNAc is a sugar
nucleotide synthesized from glucose via glycolysis, the pentose
phosphate pathway (PPP), and the hexosamine and pyrimidine
pathways14. It is involved extensively in intercellular signaling
and metabolic regulation (via O-linked glycosylation)15, 16, as well
as synthesis of the structural components of the cytoskeleton17, 18.
Similarly, the extent of 13C incorporation into many of the
NADH isotopologues reached steady state by 12 h except for
the 13C7- and 13C10-isotopologues (Fig. 2i). In comparison, the
fractional 13C enrichment of all significant ATP isotopologues
(Fig. 2h) continued to rise during the 48 h period, but was close to
isotopic steady state by 24 h. These data show that the liquid diet-
enabled tracer introduction is an effective method for studying
the complex dynamics of nucleotide and nucleotide sugar
biosynthesis in vivo, including the differential temporal behavior
of their 13C isotopologues.
Glucose metabolism differs in major organs of NSG mice. For
subsequent mouse experiments, the same liquid diet procedure as
described above was employed except that the fasting step was
omitted (Fig. 1b). To demonstrate reproducibility, we analyzed
the fractional 13C enrichment in the glycolysis and Krebs cycle
metabolites of 10 mouse livers using IC-UHR-FTMS. The
coefficients of variation were 0.044 (citrate), 0.069 (malate), 0.076
(succinate) (Krebs cycle metabolites), and 0.033 (fructose-6-
phosphate, F6P), 0.036 (glucose-6-phosphate, G6P) and 0.034
(phosphoenolpyruvate, PEP) (glycolysis metabolites) (Supple-
mentary Fig. 1a), demonstrating high reproducibility of the liquid
diet method.
To corroborate the reproducibility of data by IC-UHR FTMS,
we used 1H{13C}-HSQC NMR to determine the 13C abundances
of various metabolites in polar extracts of 5 major organs, namely
liver (Supplementary Fig. 1b) lung (Supplementary Fig. 1c), brain
(Supplementary Fig. 1d), kidney (Supplementary Fig. 1e), and
heart (Supplementary Fig. 1f) from three mice. Although there
was some variation in the eating patterns of individual mice, the
NMR spectra overlaid well for these organs, except for the
glycogen resonances in the liver (Supplementary Fig. 1b). In
addition, organ-specific 13C enrichment patterns of metabolites
were observed in these labeled mice. For example, 13C-glycogen
was observed in lung (Supplementary Fig. 1c) and liver
(Supplementary Fig. 1b) while 13C-enriched Gln, γ aminobutyrate
(GAB) and N-acetyl-aspartate (NAA) were high in brain
(Supplementary Fig. 1d), which are consistent with known
organ-specific metabolism19, 20. Moreover, 13C enrichment in the
ribose subunits of free nucleotides (5.9–6.3 ppm) was observed in
all organs, and was the highest in kidney (Supplementary Fig. 1e).
De novo synthesis of the purine and pyrimidine rings were
evident from the 13C signals in the 7.8–8.6 ppm of the liver, lung,
and heart spectra (Supplementary Fig. 1b, c and f) respectively.
Altogether, these enrichment patterns indicated active PPP and
de novo nucleobase synthesis.
We then analyzed metabolites and their 13C isotopologues
derived from multiple metabolic pathways using IC-UHR-FTMS.
13C-enriched metabolites from glycolysis (Supplementary
Fig. 2a–f), the Krebs cycle (Supplementary Fig. 2g–k), PPP
(Supplementary Fig. 3), and sugar nucleotide pathways (Supple-
mentary Fig. 4) were identified and their fractional enrichments
were determined. Considerable mixing of 13C labels (especially
the 13C3 isotopologues) in glucose-6-phosphate (G6P) and
fructose-6-phosphate (F6P) (Supplementary Figs. 2a and 3b)
was evident in all five organs. As both liver and kidney are known
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Fig. 2 Time courses of 13C enrichment of central metabolites in mouse livers fed with 13C6-glucose enriched liquid diet. WT NSG mice were necropsied at
0, 12, 36, and 48 h (n= 3 at each time point) after feeding with the 13C6-glucose liquid diet. Time courses of the fractional enrichments of 13C isotopologues
(denoted as 1-15, where the number denotes the number of 13C atoms present) of key metabolites extracted from the liver were determined by IC-UHR-
FTMS. Values represent mean± SEM (n= 3). Fractional enrichment in the 13C1 to 13C3 isotopologues (1-3) of the glycolytic products 1,3-
bisphosphoglycerate (1,3-BPG), 3-phosphoglycerate (3-PG) and lactate (a-c, main panels and insets with expanded Y-scale for the 13C1 and 13C2
isotopologues) reached steady state by 12 h. Fractional enrichment of the 13C isotopologues in the Krebs cycle products citrate d, succinate e, and malate f,
as well as pyrimidine nucleotide UTP g also reached steady state by 12 h. However the fractional enrichment in some 13C isotopologues of ATP (1-7 in h),
NADH (7,10 in i), and uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc; 6, 8 in j) continued to rise during the 48 h period of tracer feeding
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to be active in gluconeogenesis (cf. Fig. 3a) and the PPP
(Supplementary Fig. 3a), the mixed 13C labeling patterns
observed for G6P and F6P were expected in these organs. The
13C mixing of G6P or F6P in other organs could arise from
gluconeogenesis, the non-oxidative branch of PPP (cf. Supple-
mentary Fig. 3a), and/or uptake of scrambled 13C-labeled glucose
released by the liver or kidney into the circulating blood. If liver
were the sole source of the scrambled isotopic species, then we
would expect the fractional 13C enrichment of G6P and F6P to be
lower in these organs than in liver, which was not the case
(Supplementary Figs. 2a, 3b). We observed PPP activity in all 5
organs, with lung and liver being most active, as evidenced by
extensive 13C enrichment (60-95%) in the intermediates ribose-5-
phosphate (R5P, Supplementary Fig. 3c), erythrose-4-phosphate
(E4P, Supplementary Fig. 3d) and S7P (Supplementary Fig. 3e),
Thus, the PPP could variably contribute to the 13C scrambling in
G6P and F6P. Moreover, fully 13C-labeled Krebs cycle metabolites
(e.g., 13C6-citrate, 13C5-αketoglutarate (αKG), 13C4-succinate,
13C4-fumarate, and 13C4-malate) dominated in the brain
(Supplementary Fig. 2g–k), which is presumably produced from
13C6-glucose via at least 4 turns of the canonical Krebs cycle
activity and/or 2 turns of the cycle activity with anaplerotic
pyruvate carboxylation. The production of these fully labeled
species is consistent with the high Krebs cycle and anaplerotic
pyruvate carboxylase (PCB) activity in the brain21 and with the
high demand for glucose as the major carbon source in the
brain22. We further found extensive but variable 13C labeling in
UDP-GlcNAc (the 17-carbon sugar nucleotide synthesized via
glycolysis, PPP, hexosamine, the Krebs cycle, and pyrimidine
pathways, Fig. 4) including the fully labeled 13C17 species,
particularly in the brain (Supplementary Fig. 4d).
As citrate is the precursor of cytoplasmic acetyl-CoA used for
fatty acid synthesis, the high degree of labeling in citrate/isocitrate
(Supplementary Fig. 2g) suggests that the fatty acids and lipids
may also be 13C-enriched. We therefore analyzed the lipid
extracts by direct infusion nanoelectrospray (nESI) UHR-FTMS.
Liver had the highest fractional enrichment of 13C labeled
glycerolipids (lowest 13C0 or 0 isotopologue, Supplementary
Fig. 5), mainly in the fatty acyl chains (13Ceven, 13Codd> 3)
(Supplementary Fig. 5), consistent with liver’s central role in lipid
metabolism23.
The high fractional 13C enrichment in Glu also raised the
question of whether 13C-glucose-derived non-essential amino
acids support de novo protein synthesis. We tracked this process
by microwave-assisted acid hydrolysis of total protein, followed
by derivatization of released amino acids with ethyl chlorofor-
mate and analysis using nESI-UHR-FTMS24 (Supplementary
Fig. 6a). We found the highest 13C enrichment (up to 10% in the
liver) in proteinaceous amino acids to be 13C3-Ala (3,
Supplementary Fig. 6b), which is presumably derived from
glycolysis. We also found that the fractional enrichment of the
proteinaceous 13C3-Asp (3, Supplementary Fig. 6c) was generally
higher than that of 13C2-Asp in the kidney, brain, and heart. The
former isotopologue is likely to be derived from the pyruvate
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Fig. 3 A PDTX model of NSCLC shows attenuated glycolysis and enhanced malic enzyme activity and use of non-Krebs cycle-derived αKG for Glu/GSH
synthesis relative to the corresponding ex vivo tissue culture model. Mice bearing F0 PDTX (n= 3) from patient UK025 were fed the 13C6-Glc enriched
liquid diet for 18 h (cf. Fig. 1) before necropsy. Tumor tissues were dissected, weighed, and flash-frozen in liquid N2. The freshly thin-sliced UK025 tumor
tissues were cultured ex vivo in 13C6-glucose for 24 h before flash-frozen in liquid N2. Both sets of tissues were processed and analyzed by IC-UHR-FTMS
as described in Methods. a Tracing of glucose carbon through glycolysis, gluconeogenesis (GNG), the Krebs cycle, malic enzyme (ME) reactions, and
synthesis of Glu/GSH. Not all possible labeled metabolites are shown. Black circle: 12C; red circle, green circle: 13C from pyruvate dehydrogenase (PDH)
and pyruvate carboxylase (PCB)-initiated Krebs cycle reactions, respectively; pink circle: 13C derived from ME reaction; PEPCK: PEP carboxykinase. b-i
fractional enrichments in the isotopologues of phosphoenolpyruvate (PEP), citrate, α-ketoglutarate (αKG), succinate, malate, Glu, reduced glutathione
(GSH), and Asp, respectively. The x-axis denotes the number of 13C atoms present in each compound. Values shown are mean± SEM (n= 3). * 0.01< P<
0.05; ** 0.001< P< 0.01; *** P< 0.001, two-tailed t-test (see Methods)
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carboxylation pathway (cf. Fig. 3 and ref. 25). Furthermore, we
noted that 13C3-Ser (3, Supplementary Fig. 6e) incorporation into
proteins was highest in the brain. These data indicate substantial
de novo protein synthesis in all five organs during the 18 h of
tracer feeding.
PDX and ex vivo tissue cultures differ in glucose metabolism.
We then applied the method to track tumor-specific metabolic
networks in NSG mice bearing the first generation (F0) patient-
derived NSCLC tumor xenograft (PDTX) and compared them to
those of the ex vivo tumor tissue slices procured from the same
patient26, 27. Semi-quantitative 1H{13C}-HSQC NMR analysis
showed 13C labeling in numerous metabolites both in the PDX
tumor and the tumor tissue slices (Supplementary Fig. 7a),
including nucleotide ribose, glycogen, glutathiones (GSH +
GSSG), Gln, succinate, Glu, acetate and alanine. However, 13C-
labeled lactate, Ala, glutathiones, Glu, Gln, succinate, and the
ribose residue of UXP were more abundant in the PDTX than in
the matched ex vivo tumor slices. These increases in 13C abun-
dance of metabolites in PDTX are in contrast to the reduced
fractional enrichment in the 13C6-glucose input from the host
plasma (cf. 6 or 13C6 isotopologue, Supplementary Fig. 9a). They
could reflect the influence of the tumor microenvironment
(TME), such as differences in glucose uptake and/or human
versus mouse stroma.
PDTX and ex vivo tumor extracts were also analyzed by IC-
UHR-FTMS to confirm and complement the NMR analysis. We
observed high 13C enrichment in metabolites of glycolysis
(Supplementary Fig. 8), the Krebs cycle (Fig. 3), PPP (Supple-
mentary Fig. 8g, h), and nucleotides/sugar nucleotides (Supple-
mentary Fig. 8i–k) in both systems but their 13C labeling patterns
differed. Notably, lower fractional enrichment of 13C3-PEP
(Fig. 3b) and 13C3-lactate (Supplementary Fig. 8f) was evident
in the PDTX versus the ex vivo tumor tissues, which could be
related to the dilution of the 13C6-glucose input by other
unlabeled glucose source(s) in the host plasma (Supplementary
Fig. 9a) and/or attenuated glycolysis in the PDTX tissues. In
addition, the total fractional enrichment in the 13C scrambled
isotopologues of G6P (13C1 to 13C5; 1-5, Supplementary Fig. 8a),
F6P (13C1 to 13C5; 1-5, Supplementary Fig. 8b), lactate (13C1 to
13C2; 1-2, Supplementary Fig. 8f), and S7P (13C1 to 13C6; 1-6,
Supplementary Fig. 8h) were much higher in the PDTX than in
the ex vivo tumor slices, which could be related to the significant
13C scrambling of 13C6-glucose in the host plasma (Supplemen-
tary Fig. 9a). However, the 13C scrambling patterns of plasma
glucose cannot fully account for those of the products G6P and
F6P in PDTX tissues since the extent of 13C scrambling was
higher in the tissue products than the plasma input. In addition,
the fractional enrichment of the 13C3-isotopologues (a marker of
gluconeogenesis) of G6P and F6P in PDTX tissues was higher
than that of the input glucose in the plasma (Supplementary
Fig. 9a). Moreover, the 13C scrambling patterns of G6P and F6P
deviated from those of the PPP precursor S7P (Supplementary
Fig. 8h). Altogether, these results pointed to the contribution of
in situ gluconeogenesis in addition to the non-oxidative branch
activity of PPP and hepatic gluconeogenesis to the 13C
enrichment patterns of G6P and F6P in PDTX tissues, as
reasoned above. The much lower extent of 13C scrambling in
G6P, F6P, or S7P in ex vivo tumor slices suggested much reduced
activity of all three pathways, which may again reflect a TME
influence.
Tracking 13C6-glucose metabolism via the Krebs cycle (Fig. 3a),
we observed substantial fractional 13C enrichment in the 13C2-
and 13C3-isotopologues of citrate, malate, fumarate, and Asp of
both PDTX and ex vivo human tumor tissues (Fig. 3), which is
consistent, respectively, with the heightened activity of PDH and
PCB-initiated Krebs cycle (Fig. 3a) in human NSCLC tumors
observed in-patient2. We also noted much higher extent of
enrichment in 13C1-malate, -fumarate, -Asp, and -succinate in
PDTX versus ex vivo tumor tissues. These isotopologues could be
derived from the malic enzyme (ME) reaction in reverse (denoted
by pink circle in Fig. 3a). We further noted lower extent and
different patterns of 13C enrichment in αKG (Fig. 3d) versus its
expected downstream products Glu (Fig. 3g) and GSH (Fig. 3h) in
PDTXs. This result suggested the presence of additional 13C
labeled αKG to fuel Glu/GSH synthesis in PDTXs. We found
comparable level and similar patterns of 13C enrichment in
plasma Gln of the host mice (Supplementary Fig. 9b), which was
de novo synthesized from 13C6-glucose, presumably in the liver.
Thus, Glu and GSH synthesis in PDTXs could be largely fueled by
Gln in the blood rather than from αKG synthesized in situ.
Nucleotide and GSH synthesis increases in lymph node
metastases. During necropsy of the F2 generation of the above
PDTX model, we observed development of metastatic lesions in
the brachial lymph nodes, which had similar gross tumor mor-
phology (Supplementary Fig. 10a, b) and histopathology (Sup-
plementary Fig. 10c, d) as the matched primary PDTX. These
lymph node lesions stained strongly for human nucleolar antigens
(Supplementary Fig. 10d), which indicated their cells to be of
human lineage. This provided an excellent opportunity to profile
differences in metabolic activities between primary and metastatic
lesions originating from the same human tumor using the 13C
liquid diet approach. After 18 h of feeding with 13C6-glucose
enriched liquid diet, the primary and metastatic lesions were
processed and analyzed by IC-UHR-FTMS, as described in the
Methods. This analysis provided the 13C labeling patterns for
relevant metabolites, both in terms of the pool size (Fig. 4) and
fractional enrichment (Supplementary Fig. 11) of their 13C iso-
topologues, to assess the capacity for glycolysis, PPP, the Krebs
cycle, GSH metabolism, and nucleotide biosynthesis. As Fig. 4
and Supplementary Fig. 11 shows, the 13C labeling patterns were
similar between the primary tumor and lymph node lesions for
metabolites of glycolysis (cf. 13C3-lactate/pyruvate, Fig. 4b, l and
Supplementary Fig. 11b, l), gluconeogenesis (cf. 13C3-G6P, Fig. 4a
and Supplementary Fig. 11a), and the Krebs cycle including the
anaplerotic PCB (cf. 13C3-citrate/Asp, Fig. 4c, g and Supple-
mentary Fig. 11c, g), ME (cf. 13C1-malate, Fig. 4f and Supple-
mentary Fig. 11f) and canonical PDH-initiated reactions (13C2-
citrate/Asp, Fig. 4c, g and Supplementary Fig. 11c, g). These data
pointed to a similar capacity of these pathways in the two tumor
types.
Interestingly, the lymph node lesions showed consistently
higher levels of 13C incorporation from 13C6-glucose into the PPP
(Fig. 4i), GSH (Fig. 4h), and nucleotide products (Fig. 4j, k) than
the primary tumor while the 13C fractional enrichment for these
pathway products was comparable between the two tumor types
(Supplementary Fig. S1i, h, j, k). These data suggest that the
changes in capacity for these pathways in lymph node lesions was
comparable when fueled by glucose or non-glucose source(s)
since the pool sizes for the unlabeled (13C0) and 13C labeled
isotopologues of these pathway products were similarly elevated
leading to little changes in their fractional enrichment. Thus,
metastatic lesions appeared to have altered capacity for anti-
oxidation and nucleotide biosynthesis relative to primary lung
tumors, presumably to meet their survival and growth demands.
These changes could also reflect the influence of tumor size, stage,
and/or microenvironment on tumor metabolism.
BAsT cell metabolism is sensitive to the TME. To further probe
if and how cancer cell metabolism is sensitive to the TME, we
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obtained arsenite-transformed human bronchial alveolar BEAS-
2B (BAsT) cells (gift of Dr Y. Fondufe-Mittendorf, University of
Kentucky) and xenografted these cells into NSG mice to compare
glucose metabolism of the same cells in vitro versus in vivo. After
4 months of tumor growth, 3 mice were administered the 13C6-
glucose-based liquid diet for 18 h, followed by resection of tumor
tissues, extraction for polar metabolites, and analysis by NMR
and IC-UHR-FTMS. Parallel 13C6-glucose-based SIRM experi-
ments were performed on BAsT cells in vitro.
Supplementary Fig. 7b and 5 compare the central metabolic
activity of BAsT cells as tumor xenograft versus in vitro
monolayer cultures. We found multiple distinct features of the
BAsT tumor xenografts relative to cells in vitro, which were
consistent with: (1) more active glycogen synthesis (higher
abundance of 13C-glycogen, (Supplementary Fig. 7b); (2) uptake
of plasma glucose derived from hepatic gluconeogenesis
(scrambled 13C patterns of fructose-1,6-bisphosphate (F1,6BP,
a, pyruvate b, and lactate c, Fig. 5); (3) enhanced PCB-initiated
Krebs cycle activity (elevated fractional enrichment in the 13C3-
and 13C5-isotopologues of citrate d as well as 13C3- and 13C4-
isotopologues of Asp k, Malate h, fumarate g and succinate f,
Fig. 5) similar to the case of human NSCLC tumors in vivo;2, 28
(4) elevated ME activity in the reverse direction (higher fractional
enrichment of 13C1-isotopologues of malate, fumarate, succinate,
and Asp); (5) utilization of non-tumor derived 13C-αKG (e.g.,
from hepatic 13C-Gln) for Glu synthesis (total 13C fractional
enrichment of Glu i was higher than that of its precursor αKG
(Fig. 5e); (6) more favorable non-oxidative PPP (13C scrambling
in the PPP intermediate S7P (Fig. 5l) was much more extensive).
Except for (3), the rest of the metabolic features were akin to
those of the PDTXs when compared with the ex vivo tissue
counterparts (cf. Fig. 3, Supplementary Fig. 7a).
Moreover, as for the PDTX versus tissue slice case described
above, the uptake of 13C scrambled glucose from the plasma
(Supplementary Fig. 9c) could contribute to and complicate the
interpretation of the 13C labeling patterns of tumor xenograft
metabolites, particularly in terms of gluconeogenesis. However
the 13C labeling patterns of plasma glucose (e.g., dilution of 13C6-
by unlabeled glucose, Supplementary Fig. 9c) could not account
for the elevated 13C abundance of glycolytic (Lac/Ala) and Krebs
cycle metabolites (Glu/succinate/Asp) (Supplementary Fig. 7b)
and enhanced fractional enrichment of 13C-labeled Krebs cycle
metabolites. Neither could they explain the distinct scrambled
13C labeling patterns of F1,6BP (13C3-isotopologue in particular,
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Fig. 4 Lymph node metastases show enhanced PPP and biosynthesis of glutathione and nucleotides relative to the matched primary PDTX in the same
mouse. Mice bearing F2 primary PDTX and metastatic lymph node lesions (Met) (from patient UK025) were fed the 13C6-Glc enriched liquid diet for 18 h
(cf. Fig. 1) before necropsy. Tissues were processed and analyzed by IC-UHR-FTMS, as described in Fig. 3. Glucose-13C is traced through glycolysis,
gluconeogenesis (GNG), PPP, the Krebs cycle, ME reactions, and synthetic pathways of GSH, purine nucleotides (PUR), and pyrimidine nucleotides (PYR).
Not all possible labeled metabolites were shown. a–l µmole/g protein content of isotopologues of glucose-6-phosphate (G6P), lactate, citrate, αKG,
fumarate, malate, Asp, GSH, phosphoribosyl pyrophosphate (PRPP), ATP, UTP, and pyruvate, respectively in primary tumor versus lymph node metastases
(cf. Supplementary Fig. 11 for the fractional distribution of these isotopologues). The x-axis represents the number of 13C atoms present in each compound;
for ATP and UTP, “ring” is the summed value for the 13C6 to 13C9 isotopologues. All other abbreviations and symbols are as in Fig. 3. Values shown are
mean± SEM (n= 5). * 0.01< P< 0.05; ** 0.001< P< 0.01; *** P< 0.001, two-tailed t-test (see Methods)
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Fig. 5a) relative to those of the precursor S7P (Fig. 5l) or plasma
glucose (Supplementary Fig. 9c) in tumor xenografts. The latter
implicated gluconeogenic activity. Thus, our data suggested that
TME in vivo could promote anaplerotic pyruvate carboxylation,
non-oxidative branch of PPP, malic enzyme activity in the reverse
or anaplerotic direction, and gluconeogenesis.
Discussion
We have established a liquid diet that enabled non-invasive
delivery of 13C labeled glucose for in vivo metabolic studies. The
demonstrated advantages of this approach include: (1) simple
delivery of tracers without anesthesia or physical restraint; (2)
high reproducibility with coefficient of variance ranging from
0.033 to 0.076 for the Krebs cycle and glycolytic metabolites,
which will be beneficial for in vivo studies with small sample sizes
such as early generations of PDTX; and (3) much deeper coverage
of metabolic networks such that the turnover of lipids, nucleo-
tides, and protein are observable, which has been beyond the
reach of short-term, invasive methods of tracer administration.
Altogether, these advantages represent a major step forward for
in vivo metabolic studies of animal models, particularly for
examining the metabolic interactions of hosts and tumor xeno-
grafts. However, the liquid diet method may not be compatible
with very short-term tracer studies due to possible variations in
the feeding behavior. The specific method of choice for tracer
administration will depend on the question being posed.
Our findings in two types of tumor xenografts are consistent
with the metabolic scheme outlined in Supplementary Fig. 12,
where the liver supplies glucose-derived Gln via the blood to the
xenograft to fuel Glu or GSH synthesis and gluconeogenesis
occurs not only in the liver but also in the xenograft. It is also
notable that glycolysis was attenuated, glycogen synthesis was far
more active, and the ME reaction was more operative in the
anaplerotic direction in the tumor xenograft than in the corre-
sponding monolayer cell culture. The differences in cancer cell
metabolism observed for the in vivo versus ex vivo or in vivo
versus in vitro models may reflect differences in multiple
microenvironmental factors such as nutrient supply (e.g., high
glucose and glutamine ex vivo and in vitro) and exchanges (via
other organs in vivo versus culture media ex vivo and in vitro),
growth factors (mouse serum versus FBS), tumor-associated
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Fig. 5 Central metabolic activity of arsenite-transformed BAsT cells is sensitive to the tumor microenvironment. Human bronchial alveolar BEAS2B cells
were transformed by exposure to 1 µM Na2AsO3 for 18 weeks before subcutaneous xenograft of the transformed cells (BAsT cells) into NSG mice. After
4 months, mice were fed the 13C6-Glc enriched liquid diet for 18 h (cf. Fig. 1) before necropsy. Tumor tissues were processed and analyzed by IC-UHR-
FTMS as described in Fig. 3. A 13C6-Glc tracer experiment was also performed for the BAsT cells as in vitro culture for 24 h in DMEM before extraction for
polar metabolites, followed by IC-UHR-FTMS analysis (n= 3). Shown in a–c, d–k, and l are the fractional enrichments in the isotopologues of metabolites
derived from glycolysis, the Krebs cycle, and the PPP, respectively. F1,6BP: fructose-1,6-bisphosphate; S7P: sedoheptulose-7-phosphate; BAsT-C (black
square): in vitro cell cultures; BAsT-T (red square): tumor xenografts; all other abbreviations are as in Fig. 3. The x-axis represents the number of 13C atoms
present in each compound. Values shown were mean± SEM (n= 3). * 0.01< P< 0.05; ** 0.001< P< 0.01; *** P< 0.001, two-tailed t-test (see Methods)
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stroma (in vivo mouse versus ex vivo human). However, the PDX
model also displayed many metabolic similarities to the corre-
sponding ex vivo tumor tissue models; the latter metabolism in
turn recapitulates many aspects of the in vivo tumor metabolism
in human patients2. Moreover, the metabolic adaptations of
human tumor cells in the mouse stroma could have important
implications in tumor cells’ ability to survive glucose-deficiency
in vivo. For example, decreased glycolysis conserves glucose
consumption, while enhanced glycogen synthesis and accumu-
lation can serve as a glucose reserve. Increased glycogen stores
have been shown to protect cancer cells from bioenergetic stress29
and inhibition of glycogen degradation sensitized cancer cells to
glucose starvation30 or restricted their proliferation31. Gluco-
neogenesis can also supply glucose to support critical metabolic
processes. Although it is not immediately apparent as to the
benefit of enhanced ME activity, we surmise that this activity
could facilitate the utilization of non-glucose carbon sources such
as Gln to sustain the Krebs cycle activity under glucose defi-
ciency32. Future 13C-Gln-based tracer studies in vivo would help
verify this hypothesis.
In conclusion, stable isotope tracers-based mapping of meta-
bolic networks is a powerful approach to studying cancer meta-
bolism in vivo in tumor xenografts, particularly for probing the
influence of mouse TME on metabolic reprogramming in human
cancer cells. However, current in vivo labeling techniques face
important challenges including insufficient depth of pathway
coverage and stress-related artifacts. The liquid diet method
reported here is an effective and noninvasive solution to these
long-standing problems. The method can be readily extended to
animal model studies using other labeled fuel sources. Our data
also revealed complex metabolic interactions between tumors and
the host, that is challenging to resolve in the present study. This
will require the development of a multicompartment dynamic
flux model using positional isotopomer and mass isotopologue
data collected at multiple time points (cf. Fig. 2) to better and
quantitatively account for the metabolic complexity of in vivo
systems33, 34.
Methods
Animals. The NOD/SCID gamma (NSG) mouse colony was maintained in the
Division of Laboratory Animal Resources of the University of Kentucky. Initial
breeding pairs were purchased from The Jackson Laboratory (Bar Harbor, ME).
Mice were housed in a climate-controlled environment with a 1410 hours light/
dark cycle (lights on at 0600 hours) with water and solid diet (except during tracer
administration via liquid diet, see below) provided ad libitum throughout the study.
The institutional animal care and use committee at University of Kentucky has
approved all of the animal procedures carried out in this study under PHS
Assurance #A3336-01.
13C-glucose labeling of NSG mice. A liquid diet base containing casein, L-cystine,
soy oil, cellulose, mineral mix (AIN-93G-MX), calcium phosphate, vitamin mix
(AIN-93-VX), Choline Bitartrate, tert-butylhydroquinine (TBHQ), and Xanthan
gum was purchased from Harlan Laboratories (Madison, WI). S&P grade 13C6-
glucose was obtained from Cambridge Isotope Laboratories (Tewkebury, MA).
For the tracer study, unlabeled glucose and water were added to the diet base
two days prior to the tracer study to give a final diet of 0.167 g glucose/g diet and a
net protein content of 53 mg/g diet to provide sufficient carbon and nitrogen
according to the vendor. Twenty g mice were fed 13.6 g liquid diet (at 680 g diet/kg
mouse). This pre-feeding of unlabeled liquid diet served to accustom the mice to
the liquid diet feeding. On the third day, 13C6-glucose at 0.173 g/g diet replaced the
unlabeled glucose in the diet for each mouse and the mice were allowed to consume
the diet ad libitum for 18 h. At the end of the feeding period, mice were sacrificed
by spinal dislocation and organs were harvested and snap frozen in liquid nitrogen.
The frozen tissues were pulverized into 10 μm particles in liq. N2 using a Spex
freezer mill (Spex). 300 mg of each pulverized tissue were extracted in acetonitrile/
water/chloroform (V/V 2:1.5:1) and separated into polar, lipid, and protein
fractions35.
Cell culture and 13C-glucose labeling in vitro. An arsenite-transformed BEAS-2B
(BAST) lung epithelial cell line36 was maintained in DMEM supplemented with 10
mM glucose, 2 mM Gln, 10% heat-inactivated FBS and 1% penicillin–streptomycin
in 10 cm dishes. For the tracer experiment, BAST cells were allowed to reach ~
50% confluency, followed by the addition of DMEM base media supplemented
with 10 mM 13C6-glucose, 2 mM Gln, 10% dialyzed fetal bovine serum, 50 U/mL
penicillin, and 50 µg/ml streptomycin for 24 h in a CO2 incubator maintained at 37
°C. The enrichment in 13C6-glucose was > 99%. At the end of incubation, cells were
washed with cold PBS three times followed by extraction with acetonitrile/water/
chloroform (V/V 2:1.5:1) and separated into polar, lipid, and protein fractions35.
Human lung cancer slices and 13C-glucose labeling ex vivo. Fresh non-small cell
lung cancer specimens were obtained at surgery from a diagnosed, early-stage
patient (UK025) in March 2015. Written informed consent was obtained from the
patient and the study was approved by the University of Kentucky Internal Review
Board under 14-0288-F6A.
Fresh cancerous (CA) and surrounding non-cancerous (NC, distal and
proximal to CA) lung tissues were collected at the operating room within 5 min of
surgical resection, tissues were thinly sliced by the surgeon at ~0.7–1 mm thickness
with wet weights of ~8–30 mg tissue slices, as previously described37, 38. All tissue
slices were incubated in glucose and Gln-free DMEM media (Sigma-Aldrich, St.
Louis, MO) supplemented with 0.45% unlabeled or 13C6-glucose (Cambridge
Isotope Laboratories, Tewksbury, MA), 2 mM Gln, 10% dialyzed fetal bovine
serum, 50 U/mL penicillin, and 50 µg/mL streptomycin (Fisher Scientific,
Waltham, MA) for 24 h at 37 °C/5% CO2 with gentle rocking to facilitate nutrient
supply and waste product dilution37, 38. At the end of incubation, tissue slices were
quickly rinsed in cold PBS 3 times to remove medium components, blotted dry,
weighed on a 4- place balance for wet weight, and flash-frozen in liquid N2. The
frozen tissues were pulverized to 10 μm particles in liq. N2 using a Spex freezer mill
(Spex). 20 mg of each pulverized tissue were extracted in acetonitrile/water/
chloroform (V/V 2:1.5:1) and separated into polar (aqueous layer), lipid
(chloroform layer) and protein (interfacial layer) fractions35.
Mouse PDTX Models. Surgical tumor samples were cut into ca. 2 mm pieces and
transplanted within 30 min s.c. into two immunodeficient NSG mice at both left
and right flanks. The gender of the mice was chosen to match that of the donor
patient. Mice were observed daily for tumor growth. When the tumor reached
about 1 cm3 in size, both mice were fed 13C6-glucose enriched liquid diet for 18 h
before necropsy. A portion of the tumors were removed immediately and snap
frozen in liquid N2, while the rest of the tumors were cut into 2 mm pieces and re-
implanted into NSG mice for propagation. The frozen tumors were pulverized and
extracted as described above.
Cell line xenograft model. Arsenite-transformed BEAS-2B (from ATCC, certified
and mycoplasma free) (BAsT) NSCLC cells36 were suspended in PBS (5 × 106 in
100 μl) and injected subcutaneously at both left and right flanks of NSG mice.
Tumors were allowed to develop to 1 cm3 in size. Mice were then fed the 13C6-
glucose enriched liquid diet for 18 h before necropsy. A blood sample was taken
from the submandibular vein into a K3-EDTA blood tube for plasma isolation
before the mice were killed by cervical dislocation. Tumors and other tissues were
removed immediately after euthanizing and snap frozen in liquid N2. The frozen
tumors were pulverized and extracted as described above.
Polar metabolite analysis by NMR spectroscopy. NMR spectra were recorded at
14.1 T and 15 °C on a Varian DD2 spectrometer equipped with a 3 mm inverse
triple resonance cold probe. 1D 1H NMR spectra were recorded with an acquisition
time of 2 s, a recycle time of 6 s to minimize peak saturation, and continuous rf
presaturation of the residual water resonance at 4.88 ppm. 1D 1H-{13C} HSQC
spectra were recorded with an acquisition time of 0.25 s, a recycle time of 2 s, and
adiabatic decoupling of the 13C. Proton spectra were typically processed with zero
filling to 131k points, and apodized with an unshifted Gaussian and a 0.5 Hz line
broadening exponential. HSQC spectra were processed with zero-filling to 16 k
points and apodized using an unshifted Gaussian function and 4 Hz line broad-
ening. Concentrations of metabolites and 13C abundance were determined by peak
integration of the 1H or HSQC NMR spectra referenced to the intensity of DSS-d6
methyl protons, with correction for differential relaxation, as previously
described39.
Polar metabolite analysis by IC–MS. Polar fractions were reconstituted in 30 μl
nanopure water, and analyzed on a Dionex ICS-5000+ion chromatograph inter-
faced to an Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher Scientific,
San Jose, CA, USA) operating at a resolution setting of 500,000 (FWHM at m/z
200) on MS1 acquisition to capture any and all 13C isotopologues40. The Orbitrap
Fusion was tuned and calibrated according to the manufacturer’s default standard
recommendations, to routinely achieve a mass accuracy of 0.5 ppm or better. The
chromatograph was outfitted with a Dionex IonPac AG11-HC-4 µm RFIC&HPIC
guard (2 × 50 mm) guard column upstream of a Dionex IonPac AS11-HC-4 µm
RFIC&HPIC (2 × 250mm) column. An m/z range of 80–700 except for the organ
extracts where the m/z range was 50-750. Peak areas were integrated and exported
to Excel via the TraceFinder 3.3 (Themo) software package. Peak areas were cor-
rected for natural abundance distribution of each of the isotopologues41, after
which fractional enrichment and µmoles metabolites/g protein were calculated to
quantify 13C incorporation into various pathways.
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Lipid analysis by mass spectrometry. Lipid extracts were dissolved in chloro-
form/methanol (2:1, v/v) containing 1 mM butylated hydroxytoluene (BHT) as
antioxidant and subjected to MS analysis using an Orbitrap Fusion interfaced to a
TriVersa NanoMate (Advion Biosciences, Ithaca, NY, USA) nanoelectrospray
outfitted with a “D” chip (nozzle inner diameter 4.1 μm). Aliquots of lipid extracts
were diluted 10-fold in solvent A (2-propanol/methanol/chloroform, 4:2:1, v/v/v,
containing 20 mM ammonium formate) and B (methanol) for positive and nega-
tive ion mode analysis, respectively. Samples were placed into cleaned 96-well
plates, sealed with PTFE-lined seals (type BST-9790, Laboratory Supply Dis-
tributors Corp, Vineland, NJ, USA), and the plate kept at 4 °C during automated
runs on the Nanomate to reduce sample evaporation/condensation in the sealed
wells, as well as to maintain analyte stability. Nanoelectrospray ionization was
initiated from the nozzle by applying 1.6 kV with a 0.6 psi head pressure in positive
ion mode, and 1.5 kV and a 0.5 psi head pressure in the negative ion mode. All
UHR-FTMS data were recorded in profile mode using a maximal injection time of
100 ms, automated gain control at 2.5 × 105, five microscans, and a target resolu-
tion of 500,000 (FWHM at m/z 200). The Orbitrap Fusion was tuned and cali-
brated according to the manufacturer’s default standard recommendations, to
routinely achieve a mass accuracy of 0.5 ppm or better. Assignments for various
lipid classes and their isotopologue distributions were determined using our in-
house m/z-alignment & matching software Precalculated Exact Mass Isotopologue
Search Engine (PREMISE)42. The fractional 13C enrichment in lipid species was
calculated after natural abundance correction41, 42. Isotopologue distributions were
shown for different lipid classes as the unlabeled fraction (m0), the fraction in
which only the glycerol subunit was enriched at all three positions (m3), the
fraction in which only the acyl chains were enriched (summed acetyl units, “even”)
and the fraction in which both the glycerol and the acyl chains were 13C-enriched
(odd > 3)2, 42.
Protein hydrolysis and assignment by mass spectrometry. The extracted pro-
tein was precipitated with 10% trichloroacetic acid (TCA), then hydrolyzed into
free amino acids in 6N HCl using a focused beam microwave (CEM Discover) at
160 °C for 10 min. Subsequently, samples were freeze-dried to remove HCl, fol-
lowed by ethyl chloroformate (ECF) derivatization, as previously described43.
Following derivatization, ECF derivatives were introduced into the Orbitrap Fusion
by direct nanoelectrospray using the Nanomate (operated at 1.5 kV and 0.5 psi
head pressure for positive mode). The maximum ion time for the automatic gain
control (AGC) on the Orbitrap was set to 100 ms. Five transients were added to
produce each stored spectrum. Spectra were acquired for 15 min.
Statistical analyses. Metabolite quantifications are given as mean± S.E.M. For
isotope enrichments (i.e., above natural abundance), significance was tested with a
one tailed t-test with the null hypothesis of no enrichment. With the measured
SEM and n = 3, we determined that the minimum enrichment that reaches sta-
tistical significance was 0.02–0.05. For comparing means a two-tailed unpaired t-
test was used. For comparing enrichments in organs a paired t-test was used,
corrected for false discovery, as described in refs. 44, 45. Variances were close
enough to justify the t-test assuming equal variance. A P value of< 0.05 was
considered significant. *0.01 < P< 0.05; ** 0.001< P< 0.01; *** P< 0.001. Statistics
were calculated using either GraphPad or Kaleidagraph (Synergy software).
Data availability. Metabolic data are available from the authors upon request and
will be made available to the community via the Metabolomics Workbench (www.
metabolomicsworkbench.org). The authors declare that all the other data sup-
porting the findings of this study are available within the article and its Supple-
mentary Information files and from the corresponding author upon reasonable
request.
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